FDA Clears Pfizer Coronavirus Vaccine for Young Children
A C.D.C. study suggests that 42 percent of children aged 5 to 11 have coronavirus antibodies from prior infection, prompting some F.D.A. advisers to ask if one dose would be sufficient for children. Use of that study has been questioned by some scientists. F.D.A. panelists also asked whether only those with high-risk medical conditions, such…